Watanabe Yoshiki, Tanaka Shinzo, Hasebe Koki, Hiratsuka Yasuyuki, Yoshida Takao, Kusano Junko, Hori Shusei, Okamura Kana, Tanaka Chisato, Fujikawa Shiori, Osada Yuka, Minoyama Manabu
Department of Otolaryngology-Head & Neck Surgery, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Department of Otolaryngology-Head & Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Laryngoscope. 2023 Jun;133(6):1415-1424. doi: 10.1002/lary.30316. Epub 2022 Aug 3.
End-flexible-rigidscopic transoral surgery (E-TOS) is a new and minimally invasive transoral surgery for resection of Tis-selected T3 pharyngolaryngeal cancers. We evaluated long-term oncological outcomes and whether postoperative voice and swallowing function were preserved following E-TOS.
In this retrospective single-center study, 154 patients treated with E-TOS using a curved retractor, flexible-tip rigid endoscope, and thin curved instruments were included. Their survival rate, larynx preservation rate, and disease control rate were estimated using the Kaplan-Meier method. Postoperative voice function was evaluated using both objective and subjective tests. Postoperative swallowing function was assessed using the Hyodo score and the functional outcome swallowing scale.
The 3-year and 5-year overall survival, disease-specific survival, disease-free survival, laryngectomy-free survival, local control, and loco-regional control rates post E-TOS were 89.8% and 82.2%, 95.6% and 92.3%, 78.5% and 70.3%, 87.2% and 80.9%, 93.9% and 92.5%, and 87.2% and 85.7%, respectively. Both objective and subjective postoperative voice and swallowing function tests were within normal limits in more than 90% of the patients.
E-TOS is an effective, safe, low-cost, and minimally invasive transoral surgery for Tis-selected T3 pharyngolaryngeal cancer; it also preserves postoperative voice, larynx, and swallowing function.
4 Laryngoscope, 133:1415-1424, 2023.
经口软硬镜联合手术(E-TOS)是一种新型的微创经口手术,用于切除Tis期至T3期的咽喉癌。我们评估了E-TOS术后的长期肿瘤学结局以及语音和吞咽功能是否得以保留。
在这项回顾性单中心研究中,纳入了154例使用弯曲牵开器、软头硬镜和细弯器械接受E-TOS治疗的患者。采用Kaplan-Meier法估计其生存率、喉保留率和疾病控制率。术后语音功能通过客观和主观测试进行评估。术后吞咽功能采用Hyodo评分和吞咽功能结局量表进行评估。
E-TOS术后3年和5年的总生存率、疾病特异性生存率、无病生存率、无喉切除术生存率、局部控制率和区域控制率分别为89.8%和82.2%、95.6%和92.3%、78.5%和70.3%、87.2%和80.9%、93.9%和92.5%、87.2%和85.7%。超过90%的患者术后语音和吞咽功能的客观和主观测试均在正常范围内。
E-TOS是一种有效、安全、低成本且微创的经口手术,用于治疗Tis期至T3期的咽喉癌;它还能保留术后语音、喉和吞咽功能。
4 喉镜,133:1415 - 1424,2023年。